Skeletal muscle relaxant with sedative effects on the central nervous system. It is metabolized to meprobamate.Indicated on low back pain. It is excreted into breast milk in a clinically non-significant amount (Nordeng 2001, Bailey 2002, Briggs 2008) without problems being observed on infants whose mothers were receiving this medication, (Nordeng 2001), except for a mild sedation with higher maternal drug doses (Briggs 2008) .Plasma levels in the infant were undetectable (Briggs 2008). Carisoprodol use increases the risk of abuse and addictive behavior, intoxication and possible psychomotor impairment (Bailey 2002, EMA 2007) being such a reason to be withdrawn from the market in some countries. The European Medicines Agency (EMA) has recommended to withhold authorizations for marketing of medicines that contains Carisoprodol (EMA 2007, Reeves 2012, Bramases 2012). If administered during breastfeeding, it is advisable to use a minimum effective dose and monitor a possible sedation on the infant and an inadequate milk production (Sachs 2013).